selpercatinib + itraconazole

**Selpercatinib + itraconazole** is a combination of two small molecule drugs: selpercatinib, a selective inhibitor of the rearranged during transfection (RET) receptor tyrosine kinase, and itraconazole, a broad-spectrum triazole antifungal agent. Selpercatinib is primarily used in the treatment of RET-driven non-small cell lung cancer, medullary thyroid cancer, and RET-fusion positive thyroid cancers. Itraconazole is indicated for various systemic and superficial fungal infections. Itraconazole is a known strong inhibitor of cytochrome P450 3A4 (CYP3A4), which markedly increases the serum concentration of selpercatinib, requiring dose adjustments when used concomitantly. The interaction is clinically significant, as increased selpercatinib exposure can raise the risk of toxicity, including hepatotoxicity and QT prolongation[1][2][5].

Other names

selpercatinibitraconazole